美国华人生物医药科技协会(CBA)第23届年会

 

美国华人生物医药科技协会(Chinese Biopharmaceutical Association,简称CBA-USA)第23届年会经过近一年的精心策划多方联络将于6月9日在在AstraZeneca/MedImmune位于马州盖城的北美总部隆重举行。CBA年会是了解当前生物科技医药发展动态,会见当地生物企业和研究机构顶尖人物,开展业务拓展的极佳机会。本次年会的主题是“创新,创业,创机遇,迎接全球生物制药新时代”。届时,来自全球科研界、工业界、医疗界的杰出代表将展示当前生物研究前沿,结合尖端技术与技术产业化为宗旨,共同推动中美乃至全球生命医学领域的创新发展。

          免疫肿瘤界大牛耶鲁大学教授陈列平博士, Sonofi 全球研发资深副总裁刘勇军博士, Richard Pazdur 博士(Director of OCE, FDA),  Laurence JN Cooper 博士( CEO, Ziopharm) 齐聚一堂,中美医药界大拿们分享过去一年行业飞速进展,同时还有十余家生物医药公司现场招聘。

阅读:  华人生物医药科技协会第四次职业发展研讨会成功举办

在此,我们真诚地邀请您出席本次年会,期待与您一起见证生物生命医学领域的一大盛事!注册网址:http://Goo.gl/gaeEDr

 

年会主讲人介绍:

Lieping Chen, MD, PhD  陈列平 医学博士

联合技术公司癌症研究教授,耶鲁大学医学院皮肤病与免疫生物学教授;耶鲁癌症中心癌症免疫学联合主任

作为癌症免疫学的国际领先者,陈列平博士做出了一项具有里程碑意义的发现,即确定利用人体免疫系统攻击癌症的机制(PD-1 and PD-L1)。该机制彻底改变了癌症免疫疗法,并使免疫疗法在全球范围内成为现实。他在癌症治疗中发现PD-1 / PD-L1的工作被引用为2013年国际领先科学杂志“Science”排名第一的重要突破。陈列平博士正在通过开发癌症免疫靶向治疗来发展这一成果 – 在康涅狄格州开设新的生物技术公司来开发下一代疗法。陈博士撰写了300多种科学出版物,并担任州,联邦和国际研究机构和制药公司的委员会和咨询委员会成员。因为他的世界闻名的发现,陈博士获得过许多荣誉包括William B. Coley奖(2014年),AAI-Steinman奖(2016年)和Warren Alpert Foundation 奖(2017年)以及2018年Luminary奖, 被誉为“现代肿瘤免疫治疗之父”.

United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and Medicine, Yale School of Medicine; Co-Director, Cancer Immunology Program at Yale Cancer Center.

An international leader in Cancer Immunology, Dr. Chen made the landmark discovery that defined a mechanism to harness the human immune system to attack cancer (PD-1 and PD-L1), which has revolutionized cancer immunotherapy and made immune therapies a reality on a global scale. His work in the discovery of the PD-1/PD-L1 pathway in cancer therapy was cited as the #1 breakthrough of the year in 2013 by the leading international journal, Science. No less importantly, Dr. Chen is building on this success by developing new targets for cancer immunotherapy, and he is starting new biotechnology companies in Connecticut that will develop the next generation of therapies. Dr. Chen has authored more than 300 scientific publications and has served on committees and advisory boards for state, federal, and international research organizations and pharmaceutical companies. His many honors include the William B. Coley Award (2014), the AAI-Steinman Award (2016), and the Warren Alpert Foundation Prize (2017) for his world-renown discoveries. Dr. Chen was honored for the 2018 Luminary Award as “Father of Immunotherapy”.

Laurence J.N. Cooper, M.D., Ph.D. 医学博士

CHIEF EXECUTIVE OFFICER  首席执行官

 

ZioPHARM

 

在2015年5月成为ZIOPHARM首席执行官之前,Laurence Cooper博士是德克萨斯大学MD安德森癌症中心(MDACC)的终身教授,专攻儿科和免疫学。他还担任MDACC儿童癌症医院细胞治疗部主任。作为MDACC的访问科学家,他将继续领导科学工作,开发将基因工程与免疫治疗配对的新治疗方法。 Cooper博士撰写了数十篇期刊文章,摘要和书籍章节。他已经在输注T细胞和NK细胞新药临床开发了多项试验。他正在采用基于睡美人转座子/转座酶系统的基因治疗新方法的第一个方案,并帮助开发临床级人工抗原呈递细胞,用于数字扩增和活化淋巴细胞。库博博士在克利夫兰凯斯西储大学学习并获得博士和医学博士学位,后在西雅图的弗雷德哈钦森癌症研究中心接受小儿肿瘤学和骨髓移植培训。

Prior to becoming the Chief Executive Officer of ZIOPHARM in May 2015, Dr. Laurence Cooper was a tenured Professor (early/exceptional promotion) at The University of Texas MD Anderson Cancer Center (MDACC), with joint appointments in the Division of Pediatrics and Department of Immunology. He also served as Section Chief of Cell Therapy at the Children’s Cancer Hospital at MDACC where, as a Visiting Scientist at MDACC, he will continue to lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies. Dr. Cooper has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He is undertaking the first protocols using a new approach to gene therapy based upon the Sleeping Beauty transposon/transpoase system and has helped develop clinical-grade artificial antigen presenting cells for numerically expanding and activating lymphocytes. Dr. Cooper obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and then training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.

Yong-Jun Liu, M.D., Ph.D. 刘勇军博士/医学博士

Head of Research, Global R&D 赛诺菲集团全球研究部总裁

 

 

刘勇军博士自2016年4月1日起担任赛诺菲集团全球研究部总裁。刘博士在加入赛诺菲之前于2014年到2016年三月间担任MedImmune,LLC的全球研究负责人和研发部资深副总裁。刘博士从2011年至2014年初担任贝勒研究所首席科学官兼副总裁。他从德克萨斯大学医学博士安德森癌症中心加入贝勒,在那里担任免疫学教授和主任 。刘博士于2002年成为德克萨斯州大学安德森癌症中心癌症免疫学研究所的创始主任在那耕耘九年,使之成为一个世界级的研究中心,与医生和基础免疫学家合作开发人类疾病(包括自身免疫性疾病,传染病和癌症)的新型治疗方法。从1991年到1997年,他是Schering-Plough免疫学研究实验室的高级研究员和首席科学家。刘博士在加州的DNAX研究所担任首席科学家职位,直到2002年。在此之前,他是法国达迪利先灵葆雅公司免疫学研究实验室的Maitre De Recherche。在他25年的研究中,刘博士为免疫学领域做出了许多开创性的贡献。他是最著名的免疫学研究者之一,拥有超过94,000次引用(Google Scholar),并在Nature,Science,Cell,Immunity,Nature Immunology和Journal of Experimental Medicine等顶级期刊发表过250多篇文章。 2009年,他获得了来自M.D. Anderson的达拉斯 – 沃斯堡生活传奇师范学院基础研究成果奖。他于2006年获得了达纳基金会人类免疫学研究奖,并于2005年获得了桑德勒哮喘研究奖,于2004年荣获乔治和芭芭拉布什研究员的创新癌症研究奖。刘博士于1984年获得医学博士学位来自中国诺尔曼白求恩大学医学院(吉林大学),1989年在英国伯明翰大学获得免疫学博士学位。

 

Dr. Yong-Jun Liu is the Head of Research, Global R&D at Sanofi since April 01, 2016. Dr. Liu was the Head of Research and Senior Vice President of Research & Development at MedImmune, LLC from January 2014 to March 2016 before joining Sanofi. Dr. Liu had been the Chief Scientific Officer and Vice President at Baylor Research Institute from 2011 to January 2014. He joined Baylor from The University of Texas M.D. Anderson Cancer Center, where he was Professor and Chair of the Department of Immunology, Director of the Center for Cancer Immunology Research and Vivian L. Smith Distinguished Chair in Immunology. In 2002, Dr. Liu joined  M.D. Anderson , where he created a world-class research center with physicians and basic immunologists working together for the development of novel therapies for human diseases, including autoimmune diseases, infectious diseases and cancer. From 1991 to 1997, he was a Senior and then Principal Scientist at Schering-Plough’s Laboratory for Immunological Research. Dr. Liu held a Principal Staff Scientist position at the DNAX Research Institute in California until 2002, when he became the founding director of the Cancer Immunology Research Institute at the University of Texas MD Anderson Cancer Center. Before that, he was Maitre De Recherche at Laboratory for Immunology Research at Schering-Plough in Dardilly, France. He had served as the Vice Chairman of Lianyungang Ideal Group Co., Ltd. and as member of Scientific Advisory Board of Tanox Inc.  During his 25 years of research, Dr. Liu has made many seminal contributions to the field of immunology. He is one of the world’s most prolific researchers in immunology, with over 94,000 citations (Google Scholar) and more than 250 published articles in top journals such as Nature, Science, Cell, Immunity, Nature Immunology and Journal of Experimental Medicine. In 2009 he received the Dallas-Fort Worth Living Legend Faculty Achievement Award in Basic Research from M.D. Anderson. He received the Dana Foundation Award for Human Immunology Research in 2006 and the Sandler Award for Asthma Research in 2005. He was honored as the George and Barbara Bush Fellow for Innovative Cancer Research in 2004. Dr. Liu received his doctor of medicine degree in 1984 from Norman Bethune University School of Medicine in China (Jilin University), and earned his Doctorate in immunology in 1989 at the University of Birmingham in the U.K.

阅读:  华人生物医药科技协会第四次职业发展研讨会成功举办

     CBA供稿       许鹏   撰稿

Be the first to comment on "美国华人生物医药科技协会(CBA)第23届年会"

Leave a comment

Your email address will not be published.




WP Facebook Auto Publish Powered By : XYZScripts.com